Back
Compare AU
Compare REIT vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck Ftse International Property (Aud Hedged) ETF (REIT) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
REIT | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 96 | 82 |
Median incremental investment | $993.50 | $674.92 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,435.28 | $2,215.80 |
Average age group | > 35 | > 35 |
Key Summary
REIT | CURE | |
|---|---|---|
Strategy | REIT.AX was created on 2019-03-29 by VanEck. The fund's investment portfolio concentrates primarily on real estate equity. The ETF currently has 839.84m in AUM and 301 holdings. REIT.AX seeks to provide investors with access to a diversified portfolio of international property securities | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 47.33m in AUM and 158 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Welltower Inc (10.70 %) Prologis Inc (7.12 %) Equinix Inc (6.11 %) | Moderna Inc (2.31 %) TG Therapeutics Inc (1.87 %) Biogen Inc (1.84 %) |
Top 3 industries | Real Estate (100.00 %) Other (5.82 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (75.36 %) Japan (4.80 %) United Kingdom of Great Britain and Northern Ireland (3.45 %) | United States (96.74 %) Switzerland (1.43 %) United Kingdom of Great Britain and Northern Ireland (1.23 %) |
Management fee | 0.43 % | 0.45 % |
Key Summary
REIT | CURE | |
|---|---|---|
Issuer | VanEck | Global X |
Tracking index | FTSE EPRA NAREIT Developed ex Australia Rental Hedged to AUD Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.43 % | 0.45 % |
Price | $16.31 | $73.86 |
Size | $838.795 million | $47.566 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.35 % | 0.03 % |
Market | ASX | ASX |
First listed date | 02/04/2019 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
REIT | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 96 | 82 |
Median incremental investment | $993.50 | $674.92 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,435.28 | $2,215.80 |
Average age group | > 35 | > 35 |
Pros and Cons
REIT | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
REIT | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |